Centessa Reports the First Patient Dosing in the P-III (ACTION) Study of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease

Published: Feb 25, 2022 | Tags: Centessa, P-III, ACTION Study, Autosomal Dominant, Polycystic Kidney Disease

Immunocore Receives EMA’s CHMP Positive Opinion for Kimmtrak (tebentafusp) to Treat Unresectable or Metastatic Uveal Melanoma

Published: Feb 25, 2022 | Tags: Immunocore, EMA, CHMP, Kimmtrak, tebentafusp, Uveal Melanoma

Moderna Receives EMA's CHMP Positive Opinion Recommending Conditional Marketing Authorization of Spikevax (COVID-19 vaccine) for COVID-19

Published: Feb 25, 2022 | Tags: Moderna, EMA, CHMP, Conditional Marketing Authorization, Spikevax, COVID-19

Genmab & Seagen Present Preliminary Results of Tivdak (tisotumab vedotin) in P-II (innovaTV 207) Trial for Head & Neck Squamous Cell Carcinoma at ASTRO 2022

Published: Feb 25, 2022 | Tags: Genmab, Seagen, Tivdak, tisotumab vedotin, P-II, innovaTV 207 Trial, Head, Neck, Squamous Cell Carcinoma, ASTRO 2022

AbbVie Reports Results of Rinvoq (upadacitinib) in P-III (U-EXCEL) Induction Study for the Treatment of Crohn's Disease

Published: Feb 25, 2022 | Tags: AbbVie, Rinvoq, upadacitinib, P-III, U-EXCEL, Induction Study, Crohn's Disease

Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) Receive the US FDA’s Approval to Treat Adults with HFpEF

Published: Feb 25, 2022 | Tags: Boehringer Ingelheim, Eli Lilly, Jardiance, empagliflozin, US, FDA, Approval, Heart Failure Left Ventricular Ejection Fraction

Vaxcyte Reports the First Patient Dosing of VAX-24 in P-I/II Study for the Prevention of Invasive Pneumococcal Disease and Pneumonia

Published: Feb 24, 2022 | Tags: Vaxcyte, VAX-24, P-I/II Study, Invasive Pneumococcal Disease, Pneumonia

Jacobio Reports the Completion of First Patient Dosing of JAB-21822 + Cetuximab in Clinical Trials for the Treatment of Colorectal Cancer

Published: Feb 24, 2022 | Tags: Jacobio, JAB-21822, Cetuximab, Colorectal Cancer

Aadi Bioscience Launches Fyarro for the Treatment of Adult Patients with Malignant PEComa

Published: Feb 24, 2022 | Tags: Aadi Bioscience, Fyarro, Malignant PEComa

Horizon Initiates P-III (OPTIC-J) Trial of Teprotumumab for the Treatment of Active Thyroid Eye Disease

Published: Feb 24, 2022 | Tags: Horizon, P-III, OPTIC-J Trial, Teprotumumab, Thyroid Eye Disease

Alimera Sciences Publishes Three Year Results of Iluvien in P-IV (PALADIN) Study for the Treatment of DME in Peer-Reviewed Journal Ophthalmology

Published: Feb 24, 2022 | Tags: Alimera Sciences, Iluvien, P-IV, PALADIN Study, DME, Ophthalmology

Cytokinetics Initiates P-III (SEQUOIA-HCM) Trial of Aficamten for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

Published: Feb 24, 2022 | Tags: Cytokinetics, P-III, SEQUOIA-HCM Trial, Aficamten, Symptomatic, Obstructive, Hypertrophic Cardiomyopathy

Kodiak Reports Results of KSI-301 in P-IIb/III Study for the Treatment of Age-Related Macular Degeneration

Published: Feb 23, 2022 | Tags: Kodiak, KSI-301, P-IIb/III Study, Age-Related Macular Degeneration

Medtronic’s InterStim X System Receives the US FDA’s Approval for the Treatment of Bladder and Bowel Control

Published: Feb 23, 2022 | Tags: Medtronic, InterStim X System, US, FDA, Approval, Bladder, Bowel Control

BioXcel Publishes Results of BXCL501 in P-III (SERENITY II) Trial for the Treatment of Bipolar Disorders in the JAMA

Published: Feb 23, 2022 | Tags: BioXcel, BXCL501, P-III, SERENITY II Trial, Bipolar Disorders, JAMA

Kiniksa Collaborated with Huadong Medicine to Develop and Commercialize Arcalyst and Mavrilimumab for Autoimmune and Inflammatory Diseases

Published: Feb 23, 2022 | Tags: Kiniksa, Huadong Medicine, Arcalyst, Mavrilimumab, Autoimmune, Inflammatory Diseases

Takeda Entered into a Collaboration and Option Agreement with Code Bio to Develop Gene Therapies for the Treatment of Rare Diseases

Published: Feb 23, 2022 | Tags: Takeda, Code, Gene Therapies, Rare Diseases 3DNA, Non-Viral, Genetic Medicine

Akebia Amended and Restated License Agreement with Vifor Pharma to Launch Vadadustat in the US

Published: Feb 23, 2022 | Tags: Akebia, Vifor Pharma, Vadadustat, US, Anemia, CKD

OBI Entered into an Exclusive License Agreement with Odeon for OBI-999 and OBI-833 to Treat Cancer in China, Hong Kong and Macau

Published: Feb 22, 2022 | Tags: OBI, Odeon, OBI-999, OBI-833, Cancer, China, Hong Kong, Macau

InnoCare Reports First Patient Dosing of Orelabrutinib in P-II Clinical Trial for the Treatment of ITP

Published: Feb 22, 2022 | Tags: InnoCare, Orelabrutinib, P-II, Clinical Trial, ITP

Janssen Presents Results of Tremfya (guselkumab) in P-II (GALAXI 1) Clinical Trial for the Treatment of Active Crohn's Disease at ECCO 2022

Published: Feb 22, 2022 | Tags: Janssen, Tremfya, guselkumab, P-II, GALAXI 1 Clinical Trial, Active Crohn's Disease

Abbott's CardioMEMS HF System Receives the US FDA’s Approval for the Treatment of Heart Failure

Published: Feb 22, 2022 | Tags: Abbott, CardioMEMS HF System, US, FDA, Approval, Heart Failure

Ono’s Velexbru Receives the TFDA’s Approval for the Treatment of B-cell Primary Central Nervous System Lymphoma in Taiwan

Published: Feb 22, 2022 | Tags: Ono, Velexbru, TFDA, Approval, B-cell Primary Central Nervous System Lymphoma, Taiwan

BioNTech Entered into a Research Collaboration with Medigene to Boost T Cell Receptor Immunotherapies Against Cancer

Published: Feb 22, 2022 | Tags: BioNTech, Medigene, T Cell, Receptor, Immunotherapies, Cancer

Medtronic’s Freezor and Freezor Xtra Cardiac Cryoablation Focal Catheters Receives the US FDA’s Expanded Approval for AVNRT

Published: Feb 21, 2022 | Tags: Medtronic, Freezor, Xtra Cardiac Cryoablation Focal Catheters, US, FDA, Expanded Approval,  AVNRT

Immunic Presents Preclinical Data of IMU-838 9 (vidofludimus calcium) in P-II (CALDOSE-1) Trial for the Treatment of Ulcerative Colitis at ECCO 2022

Published: Feb 21, 2022 | Tags: Immunic, IMU-838 9, vidofludimus calcium, P-II, CALDOSE-1 Trial, Ulcerative Colitis, ECCO 2022

Agios’ Pyrukynd (mitapivat) Receives the US FDA’s Approval as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with PK Deficiency

Published: Feb 21, 2022 | Tags: Agios, Pyrukynd, mitapivat, US, FDA, Approval, Hemolytic Anemia, PK Deficiency

EMD Serono Reports Results of Bavencio (avelumab) in P-III (JAVELIN Bladder 100) Trial as 1L Maintenance Treatment for Advanced Urothelial Carcinoma

Published: Feb 21, 2022 | Tags: EMD Serono, Bavencio, avelumab, P-III, JAVELIN Bladder 100 Trial, Urothelial Carcinoma

Eli Lilly Reports Results of Mirikizumab in P-III (LUCENT-1) Induction Study for the Treatment of Ulcerative Colitis

Published: Feb 21, 2022 | Tags: Eli Lilly, Mirikizumab, P-III, LUCENT-1, Induction Study, Ulcerative Colitis

Janssen Reports Results of Tremfya (guselkumab) in P-IIb (QUASAR) Induction Study for the Treatment of Active Ulcerative Colitis

Published: Feb 21, 2022 | Tags: Janssen, Tremfya, guselkumab, P-IIb, QUASAR, Induction Study, Ulcerative Colitis

Related Post: PharmaShots Weekly Snapshots (February 14-18, 2022)